Leukemia: all 5,475 studies

Page 42 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00991133Phase 1
• Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
• Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00990054Phase 1
• Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic LeukemiaTerminatedNCT00985530Phase 1
• Allo-Allo Tandem Bone Marrow Transplant (BMT)Status unknownNCT00984412Phase 1/2
• Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)CompletedNCT00983138Phase 2
• Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008Status unknownNCT00982514
• Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesCompletedNCT00981240Phase 1
• Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood DisordersTerminatedNCT00973804Phase 1
• Infusion of Expanded Cord Blood T CellsWithdrawnNCT00972101Phase 1
• Study of Dosage Individualisation for the Treatment of Acute Myeloid LeukemiaCompletedNCT00969891
• Intraosseous Infusion of Unrelated Cord Blood GraftsTerminatedNCT00967525Not applicable
• Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction CourseWithdrawnNCT00967512Phase 2
• Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00967057Phase 3
• Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1
• Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell TransplantCompletedNCT00964821
• Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete RemissionCompletedNCT00963521Phase 1
• Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
• Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00963274Phase 1
• Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
• Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic LeukemiaWithdrawnNCT00962715Phase 1/2
• Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute LeukemiaTerminatedNCT00961142Phase 2
• Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
• Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT00957320Phase 1
• Quality of Life in Younger Leukemia and Lymphoma SurvivorsCompletedNCT00956475
• Observational Study of Iron Overload in Stem Cell TransplantationCompletedNCT00954720
• Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy VolunteersTerminatedNCT00952185Not applicable
• A Standardized Nursing Intervention Protocol for HCT PatientsCompletedNCT00951626Not applicable
• Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00951457Phase 1/2
• Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid LeukemiaCompletedNCT00947830
• Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00947388Phase 1
• Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic SyndromeTerminatedNCT00946283Not applicable
• PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic LeukemiaTerminatedNCT00944008Phase 3
• Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 MutationsCompletedNCT00943943Phase 1
• Intensive Glycemic Control on Infectious Morbidity In Patients With Acute LeukemiaWithdrawnNCT00943709Phase 3
• A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsWithdrawnNCT00943553Phase 2
• Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaCompletedNCT00940524Phase 1
• S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00939328Phase 2
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
• Natural Killer Cells Function in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00934986Not applicable
• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or LeukemiaTerminatedNCT00933985Phase 1
• Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2CompletedNCT00931138Phase 3
• A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic LeukaemiaCompletedNCT00930098Phase 2
• A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years OldCompletedNCT00927498Phase 3
• Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)CompletedNCT00926731Phase 1
• GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyCompletedNCT00925873Phase 3
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
• A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00923182Phase 1
• Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell TransplantCompletedNCT00920842
• Metabolic Syndrome in Childhood Cancer SurvivorsCompletedNCT00920738
• S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic CancerCompletedNCT00919425
• Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic CancerTerminatedNCT00918658
• Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing RegimenWithdrawnNCT00918450Phase 2
• Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic LeukemiaStatus unknownNCT00917540
• Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
• Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesCompletedNCT00915785Phase 2
• Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00915252Phase 2
• MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
• Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)CompletedNCT00909168Phase 2/3
• Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT00908167Phase 1
• ASCT for Relapsed APL After Molecular RemissionTerminatedNCT00907582Phase 2
• Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseApproved for marketingNCT00905593
• Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT00905398Phase 1/2
• Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 1
• Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic LeukemiaCompletedNCT00902213Not applicable
• QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00900809Phase 1
• Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic LeukemiaWithdrawnNCT00900445
• Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid LeukemiaCompletedNCT00900380
• Studying Tissue and Blood Samples From Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00900224
• Collecting and Storing Blood Samples From Patients With CancerWithdrawnNCT00900120
• Blood Samples From Patients on a Clinical Trial to CINV During HSCTTerminatedNCT00900068
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or RemissionCompletedNCT00899899
• Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997CompletedNCT00899873
• Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy VolunteersCompletedNCT00899795
• S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid LeukemiaCompletedNCT00899743
• DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00899652
• DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic LeukemiaCompletedNCT00899366
• Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic SyndromesActive, not recruitingNCT00899223
• S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid LeukemiaCompletedNCT00899171
• Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070JCompletedNCT00899015
• Collecting and Storing Tissue From Young Patients With CancerCompletedNCT00898755
• Identifying Risk Factors for Bone Tissue Death in Young Patients With Acute Lymphoblastic Leukemia Treated on Clinical Trial CCG-1882CompletedNCT00898469
• Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00898456
• Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With MethotrexateCompletedNCT00898404
• Gene Expression in Tissue From Patients With Acute Lymphoblastic LeukemiaCompletedNCT00898261
• Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaStatus unknownNCT00898092
• DNA Analysis of Tumor Tissue From Patients With Acute Myeloid LeukemiaCompletedNCT00897936
• Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical TrialCompletedNCT00897767
• Study of Bone Marrow Samples From Patients With Acute LeukemiaCompletedNCT00897559
• DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic LeukemiaCompletedNCT00897507
• Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT00897325
• Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid LeukemiaCompletedNCT00897182
• Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy SiblingsCompletedNCT00897078
• Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic LeukemiaCompletedNCT00896766
• Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2CompletedNCT00896701
• Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line TherapyCompletedNCT00896129

← Leukemia overview